by Peter Ciszewski | Aug 30, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Barry Greene, President of Alnylam, discusses how his company works with advocacy groups in the diseases they are committed to.
by Peter Ciszewski | Aug 29, 2018
Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses the challenges of a small biotech company working with rare diseases, especially rare neurological disorders.
by Peter Ciszewski | Aug 29, 2018
Pfizer announced positive data from it’s phase 3 study (called ATTR-ACT), which evaluated it’s experimental therapy Tafamidis (vyndaqel) in patients with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis achieved...
by Peter Ciszewski | Aug 28, 2018
Openly Rare with Paul Kidwell is a monthly podcast series dedicated to the discussion around rare diseases. The podcast, created and hosted by Paul Kidwell, a 20-year PR veteran within the life science industry, will feature timely conversations with researchers,...
by Peter Ciszewski | Aug 27, 2018
Ron Cooper, President and CEO of Albireo, discusses his company and lead product. Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or...
